RPRX vs. LLY

Last updated Apr 1, 2026

Compare and contrast key facts about Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY).

Performance

RPRX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

RPRX vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
RPRX Royalty Pharma plc	24.80%	55.29%	-6.36%	-27.08%	0.99%	-19.09%	13.33%
LLY Eli Lilly and Company	-14.27%	40.25%	33.30%	60.91%	34.26%	66.08%	4.17%

Fundamentals

EPS RPRX : $2.06 LLY : $22.96
PE Ratio RPRX : 23.27 LLY : 40.06
PEG Ratio RPRX : 0.04 LLY : 0.81
PS Ratio RPRX : 7.54 LLY : 12.68
Total Revenue (TTM) RPRX : $2.38B LLY : $65.18B
Gross Profit (TTM) RPRX : $1.76B LLY : $54.62B
EBITDA (TTM) RPRX : $1.57B LLY : $27.94B

Returns By Period

In the year-to-date period, RPRX achieves a 24.80% return, which is significantly higher than LLY's -14.27% return.

RPRX

• 1D: 3.45%
• 1M: 3.81%
• YTD: 24.80%
• 6M: 37.44%
• 1Y: 57.76%
• 3Y*: 13.02%
• 5Y*: 4.62%
• 10Y*: —

LLY

• 1D: 3.74%
• 1M: -12.57%
• YTD: -14.27%
• 6M: 20.93%
• 1Y: 12.19%
• 3Y*: 39.90%
• 5Y*: 39.16%
• 10Y*: 30.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RPRX vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RPRX

RPRX Risk / Return Rank: 95
RPRX Sharpe Ratio Rank: 95
RPRX Sortino Ratio Rank: 93
RPRX Omega Ratio Rank: 93
RPRX Calmar Ratio Rank: 97
RPRX Martin Ratio Rank: 96

LLY

LLY Risk / Return Rank: 51
LLY Sharpe Ratio Rank: 53
LLY Sortino Ratio Rank: 48
LLY Omega Ratio Rank: 49
LLY Calmar Ratio Rank: 53
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RPRX vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RPRX	LLY	Difference
Sharpe ratio Return per unit of total volatility	2.56	0.29	+2.27
Sortino ratio Return per unit of downside risk	3.26	0.69	+2.58
Omega ratio Gain probability vs. loss probability	1.44	1.10	+0.34
Calmar ratio Return relative to maximum drawdown	7.66	0.42	+7.24
Martin ratio Return relative to average drawdown	18.39	1.02	+17.37
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RPRX vs. LLY - Sharpe Ratio Comparison

The current RPRX Sharpe Ratio is 2.56, which is higher than the LLY Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of RPRX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RPRX	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.56	0.29	+2.27
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.19	1.23	-1.03
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.04	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.13	0.56	-0.43

Correlation

The correlation between RPRX and LLY is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RPRX vs. LLY - Dividend Comparison

RPRX's dividend yield for the trailing twelve months is around 1.87%, more than LLY's 0.68% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
RPRX Royalty Pharma plc	1.87%	2.28%	3.29%	2.85%	1.92%	1.71%	0.60%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.68%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

RPRX vs. LLY - Drawdown Comparison

The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum LLY drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for RPRX and LLY.

Drawdown Indicators

	RPRX	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-49.68%	-68.24%	+18.56%
Max Drawdown (1Y) Largest decline over 1 year	-7.38%	-30.26%	+22.88%
Max Drawdown (5Y) Largest decline over 5 years	-43.44%	-34.48%	-8.96%
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	0.00%	-17.00%	+17.00%
Average Drawdown Average peak-to-trough decline	-27.22%	-19.25%	-7.97%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.07%	12.39%	-9.32%

Volatility

RPRX vs. LLY - Volatility Comparison

The current volatility for Royalty Pharma plc (RPRX) is 6.99%, while Eli Lilly and Company (LLY) has a volatility of 9.04%. This indicates that RPRX experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RPRX	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.99%	9.04%	-2.05%
Volatility (6M) Calculated over the trailing 6-month period	16.06%	26.21%	-10.15%
Volatility (1Y) Calculated over the trailing 1-year period	22.68%	42.44%	-19.76%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.20%	32.14%	-7.94%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.04%	29.80%	-2.76%

Financials

RPRX vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between Royalty Pharma plc and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Royalty Pharma plc reported a gross profit of 0.00 and revenue of 622.00M. Therefore, the gross margin over that period was 0.0%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.

RPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Royalty Pharma plc reported an operating income of 388.00M and revenue of 622.00M, resulting in an operating margin of 62.4%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.

RPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Royalty Pharma plc reported a net income of 214.00M and revenue of 622.00M, resulting in a net margin of 34.4%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.